

# Shuji Murakami

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/50120/shuji-murakami-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

5,600  
citations

15  
h-index

61  
g-index

61  
ext. papers

7,723  
ext. citations

5.5  
avg, IF

4.8  
L-index

#	Paper	IF	Citations
59	Uncommon mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901).. <i>Future Oncology</i> , <b>2022</b> ,	3.6	1
58	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
57	Radiation recall pneumonitis after COVID-19 vaccination. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
56	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 537-547	4.1	2
55	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 63-72	7.5	5
54	Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy. <i>Internal Medicine</i> , <b>2021</b> , 60, 1743-1746	1.1	3
53	Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 194-200	3.2	5
52	Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	2
51	Acute eosinophilic pneumonia after changing dosing schedule of nivolumab. <i>Japanese Journal of Clinical Oncology</i> , <b>2021</b> , 51, 1766-1767	2.8	0
50	Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 653-659	4.1	1
49	Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 1229-1236	7.4	11
48	Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2262-2269	3.2	1
47	Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1038-1044	3.2	
46	Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 15-22	7.4	25
45	Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3576-3584	3.2	2
44	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3585-3595	3.2	9
43	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 288-293	8.9	203

42	Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. <i>Japanese Journal of Clinical Oncology</i> , <b>2019</b> , 49, 793-794	2.8	17
41	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. <i>Medical Oncology</i> , <b>2019</b> , 36, 49	3.7	11
40	Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1141-1148	3.2	5
39	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 1819-1830	4.0	1272
38	Mixed response to osimertinib and the beneficial effects of additional local therapy. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 738-743	3.2	4
37	Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 815-822	3.2	10
36	Durvalumab for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 1009-1016	3.5	13
35	Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type. <i>Journal of Experimental Therapeutics and Oncology</i> , <b>2019</b> , 13, 131-138	0.8	3
34	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 521-536	21.7	315
33	Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 81-87	3.5	4
32	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2342-2350	59.2	1336
31	Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?. <i>General Thoracic and Cardiovascular Surgery</i> , <b>2017</b> , 65, 512-518	1.6	11
30	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1919-1929	59.2	2034
29	Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, e204-e211	1.9	16
28	Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2017</b> , 51, 218-222	3	4
27	Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2016</b> , 49, 293-9	3	28
26	Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , <b>2016</b> , 46, 1015-1021	2.8	5
25	Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , <b>2016</b> , 102, 1668-1673	2.7	35

24	Phase II study of gefitinib as first-line chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations and poor prognostic characteristics.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20625-e20625	2.2	
23	Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20503-e20503	2.2	
22	Phase II study of carboplatin and pemetrexed followed by gefitinib for patients with advanced non-small cell lung cancer harboring sensitive EGFR mutation.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20581-e20581	2.2	
21	Clonality analysis performed using human androgen receptor assay in a rare case of undifferentiated thymic carcinoma coexisting with type AB thymoma. <i>Pathology International</i> , <b>2016</b> , 66, 398-403	1.8	4
20	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1574-85	8.9	20
19	Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2015</b> , 47, 1022-6	3	15
18	Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. <i>Lung Cancer</i> , <b>2015</b> , 90, 199-204	5.9	38
17	Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. <i>Annals of Thoracic Surgery</i> , <b>2015</b> , 99, 975-81	2.7	30
16	A case of lung adenocarcinoma with multiple cavitory metastases. <i>Japanese Journal of Clinical Oncology</i> , <b>2015</b> , 45, 504-5	2.8	1
15	Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma. <i>Annals of Thoracic Surgery</i> , <b>2015</b> , 99, 956-60	2.7	16
14	Two Cases of Stage IV Lung Adenocarcinoma That Achieved a Long-term Survival on Gefitinib. <i>Japanese Journal of Lung Cancer</i> , <b>2015</b> , 55, 1029-1036	0.1	0
13	Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group 0910. <i>Anticancer Research</i> , <b>2015</b> , 35, 6705-11	2.3	7
12	Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the initiation of irinotecan-based chemotherapy. <i>Molecular and Clinical Oncology</i> , <b>2014</b> , 2, 737-743	1.6	5
11	Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19125-e19125	2.2	
10	The clinical value and prognostic role of preoperative thin-section computed tomography findings in small-sized adenocarcinomas of the lung (10 mm or less in diameter).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e18514-e18514	2.2	
9	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 705-11	3.5	6
8	$^{18}$ F-fluorodeoxyglucose uptake on positron emission tomography in mucinous adenocarcinoma. <i>European Journal of Radiology</i> , <b>2013</b> , 82, e721-5	4.7	10
7	Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy. <i>Internal Medicine</i> , <b>2013</b> , 52, 589-91	1.1	8

6	The usefulness of UGT1A1 polymorphism testing before starting irinotecan-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11055-11055	2.2	
5	Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7531-7531	2.2	
4	Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer. <i>Journal of Experimental Therapeutics and Oncology</i> , <b>2013</b> , 10, 203-8	0.8	
3	Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma. <i>European Journal of Radiology</i> , <b>2012</b> , 81, 1891-5	4.7	11
2	Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. <i>Lung Cancer</i> , <b>2010</b> , 69, 361-4	5.9	14
1	Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. <i>European Journal of Radiology</i> , <b>2010</b> , 75, e62-6	4.7	18